CD38 and infection: A significantly higher risk for breakthrough infections was observed in patients treated with anti-CD38 mABs (HR 2.55; 95% CI 1.18–5.24, p = 0.01), while no significant association was seen for the parameters anti-CD20 mAB treatment, age ≥ 65 or auto/alloSCT (Figure 3).